Navigation Links
Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company's Board of Directors
Date:1/3/2012

BROOMFIELD, Colo., Jan. 3, 2012 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative therapeutics to treat central nervous system disorders, announced today that Holger Kunze has been appointed to the position of Chief Executive Officer and as a member of the company's Board of Directors (BoD).  Concurrently, Sven Thormahlen, Ph.D., has also been appointed as a member of Accera's BoD.

With more than 30 years managerial experience with multinational pharmaceutical and nutrition companies, Mr. Kunze currently serves as the Regional Business Unit Head for Nestle Health Science's HealthCare Nutrition Business Unit in the Africa, Oceania and Asia (AOA) territories.  While managing more than 600 employees, Mr. Kunze integrated the Novartis Medical Nutrition Business into the Nestle Nutrition Division, leading it to one of the top Medical Nutrition companies in the region with more than $250M in sales for 2011.  Under his leadership, Nestle Health Science consistently delivered annual targeted top and bottom line performance and gained market share in all markets.

Prior to joining Nestle, Mr. Kunze held various managerial positions within Novartis for more than 10 years.  Most recently, Mr. Kunze led and managed the consumer health division of the Asia Regional Novartis Medical Nutrition business unit from 2004 to 2007.  During his tenure, Mr. Kunze established the Asia Regional Medical Nutrition Office in Singapore, supported and coordinated the acquisition of the Mead Johnson Adult Nutrition business and led and managed the Medical Nutrition businesses for Novartis in 17 Asian countries. 

"I am thrilled to have the opportunity to add to Accera's efforts of providing Alzheimer's patients with an alternative for managing their disease," said Mr. Kunze.  "I'm confident that with my experience, we'll be able to further expand the commercial presence of Axona in global markets."

Dr. Sven Thormahlen has more than twenty years experience in successfully managing industrial research and product development departments with emphasis on fast moving consumer goods, medical devices, OTC products and medical nutrition.  He currently serves as the CEO of MucoVax, a biological immune care company based in Germany.  Prior to this role, Dr. Thormahlen served as the International executive director of research and development at Groupe Danone in France until May 2011.  In this role, Dr. Thormahlen headed more than 1,500 researchers while overseeing four divisions, including medical nutrition, dairy foods, waters and beverages and baby and infant nutrition.

"We are delighted to be joined by Mr. Kunze and Dr. Thormahlen," said Claude Nash, Ph.D., head of Accera's BoD.  "We are confident their extensive experience with international pharmaceutical companies and medical nutrition will further Accera's goal of developing novel therapeutic products for neurodegenerative diseases."

About Axona®
Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. For more information about Axona, please visit www.about-axona.com or ask your physician.

About Accera, Inc.
Accera, Inc. is a privately held commercial-stage biotechnology company that developed and now markets Axona in the US.  Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases.  For more information about Accera, please visit www.accerapharma.com.Contacts:  

Tiberend Strategic Advisors, Inc.Accera, Inc.

(212) 827-0020(303) 999-3705

Andrew MielachBill Poncy

amielach@tiberend.comVP Commercial Development

or bponcy@accerapharma.com

Stephanie Denis 

sdenis@tiberend.com 


'/>"/>
SOURCE Accera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimers Disease
2. Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
3. Inova Selects Beryl as Provider of Outsourced Patient Experience Solutions
4. WHCA Selects COMS Interactive as Affinity Partner
5. Tidewell Hospice Selects Allscripts Homecare and Financial Management Solutions
6. Top 3 Clinical Research Organization Selects QTinno for a Phase I Drug Safety Trial
7. Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange
8. The Association of Telecom Professionals Selects Dr. Jay Yadav, CardioMEMS Founder & CEO, as an Atlanta Telecom Professional of the Year in the Industry Innovation Category
9. DMC Childrens Hospital of Michigan Selects Allscripts Electronic Health Record for Employed and Affiliated Physicians
10. Brown & Toland Physicians Selects Allscripts Community Record to Connect 1,500 Bay Area Physicians
11. WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... growth in the United States will continue in 2017, ... their December 2016 Semiannual Economic Forecast. Expectations are for ... mid-2009, as indicated in the monthly ISM ® ... sector is optimistic about growth in 2017, with revenues ... non-manufacturing sector indicates that 14 of its industries will ...
(Date:12/8/2016)... , Dec. 8, 2016  Avelas Biosciences, ... improving cancer patient care from diagnosis through treatment, ... recently completed Phase 1b study in breast cancer ... San Antonio Breast Cancer Symposium. Jonathan Unkart ... at UC San Diego Health, delivered the presentation ...
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... today that it will charge enterprise customers only when ... model disrupts the health and wellness sector, which typically ... Logo - http://photos.prnewswire.com/prnh/20161207/446824LOGO ... platform  combines the power of technology with the empathy ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift ... lines by smoothing and tightening the skin of the face to create more ... facial aging with very little downtime, Silhouette Instalift is a novel, minimally invasive ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning of ... an emergency medical call when he lost control of his patrol car. The vehicle ... his vehicle, he was transported to Atlanta Medical Center, where he later succumbed to ...
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is now ... to restore a more youthful appearance to the face. Dr. Peyman Ghasri and Dr. ... a variety of other treatments, to rejuvenate and renew the facial appearance. , ...
(Date:12/7/2016)... Ill. (PRWEB) , ... December 07, 2016 , ... Levels ... early-stage brain damage, according to a study appearing online in the journal Radiology. , ... is expected to increase significantly due to the rapidly aging population. Damage to both ...
Breaking Medicine News(10 mins):